Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Apathy Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

3 recruiting trials for Apathy. Eligibility criteria explained in plain English.

TrialFinderData lists 3 Apathy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 2: 1, Phase 3: 1.

Research is led by Sunnybrook Health Sciences Centre (1), Riccardo Guglielmo (1), Louisiana State University Health Sciences Center Shreveport (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is intermittent theta burst stimulation (iTBS) (device, 1 trial), followed by Methylphenidate (MPH), Esketamine (Intranasal Spray).

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
3
Total Trials
3
Recruiting Now
1
Phase 3 Trials
3
Sponsors

Track Apathy trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT07279740

Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia

This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 121 location
RECRUITINGNCT07146503

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the...

Sponsor: Riccardo GuglielmoEnrolling: 1005 locations
RECRUITINGPhase 3NCT06482554

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by...

Sponsor: Louisiana State University Health Sciences Center ShreveportEnrolling: 801 location

Frequently Asked Questions

There are currently 3 clinical trials for Apathy, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Apathy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Apathy, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.